SEOM clinical guidelines for the diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) 2014

Por Garcia-Carbonero, R., JImenez-Fonseca, P., Teulé, A., Barriuso, J., Sevilla, I.
Publicado no Clin Transl Oncol (2014)

Clinical management of regorafenib in the treatment of patients with advanced colorectal cancer

Por Sastre, J., Argilés, G., Benavides, M., Feliú, J., García-Alfonso, P., García-Carbonero, R., Grávalos, C., Guillén-Ponce, C., Martínez-Villacampa, M., Pericay, C.
Publicado em 2014

SEOM clinical guidelines for diagnosis and treatment of metastatic colorectal cancer 2015

Por Aranda, E., Aparicio, J., Alonso, V., Garcia-Albeniz, X., Garcia-Alfonso, P., Salazar, R., Valladares, M., Vera, R., Vieitez, J. M., Garcia-Carbonero, R.
Publicado no Clin Transl Oncol (2015)

PD-029 Baseline carcinoembryonic antigen (CEA) as a predictive factor of ramucirumab efficacy in RAISE, a second-line metastatic colorectal carcinoma (mCRC) phase 3 trial

Por Yoshino, T., Obermannová, R., Bodoky, G., Garcia-Carbonero, R., Ciuleanu, T.-E., Portnoy, D., Kim Tae, W., Hsu, Y., Yang, L., Ferry, D., Nasroulah, F., Tabernero, J.
Publicado no Ann Oncol (2016)

Efficacy of trifluridine and tipiracil (TAS-102) versus placebo, with supportive care, in a randomized, controlled trial of patients with metastatic colorectal cancer from Spain: r...

Por Longo-Muñoz, F., Argiles, G., Tabernero, J., Cervantes, A., Gravalos, C., Pericay, C., Gil-Calle, S., Mizuguchi, H., Carrato-Mena, A., Limón, M. L., Garcia-Carbonero , R.
Publicado no Clin Transl Oncol (2016)

PD-012 Analysis of patients ≥75 years in the open-label phase 3b CONSIGN trial of regorafenib in previously treated metastatic colorectal cancer (mCRC)

Por Van Cutsem, E., Ciardiello, F., Ychou, M., Seitz, J.-F., Hofheinz, R., Arriaga, Y., Garcia-Carbonero, R., Grothey, A., Miriyala, A., Kalmus, J., Kappeler, C., Falcone, A., Zaniboni, A.
Publicado no Ann Oncol (2016)

Subgroup analysis in RAISE: a randomized, double-blind phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metast...

Por Obermannová, R., Van Cutsem, E., Yoshino, T., Bodoky, G., Prausová, J., Garcia-Carbonero, R., Ciuleanu, T., Garcia Alfonso, P., Portnoy, D., Cohn, A., Yamazaki, K., Clingan, P., Lonardi, S., Kim, T. W., Yang, L., Nasroulah, F., Tabernero, J.
Publicado no Ann Oncol (2016)

PD-025 RECOURSE trial: impact of adverse events on quality of life and duration of TAS-102 (trifluridine and tipiracil) treatment

Por Tabernero, J., Mayer Robert, J., Ohtsu, A., Yoshino, T., Garcia-Carbonero, R., Pastorino, A., Peeters, M., Winkler, R., Makris, L., Wahba, M., Zaniboni, A., Shimada, Y., Yamazaki, K., Komatsu, Y., Hochster, H., Lenz, H.-J., Falcone, A., Tran, B., Van Cutsem, E.
Publicado no Ann Oncol (2016)